NASDAQ · Biotechnology

AMLX (AMLX) Stock

$22.82 -5.66% NASDAQ: AMLX Healthcare

Valuation

MetricValue
Price$22.82
Market Cap$2.54B
P/E Ratio-8.69
P/B Ratio3.62
P/S Ratio0.00
EPS (TTM)$-1.53
52-Week High$22.82
52-Week Low$4.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-47.54%
ROA-43.54%
ROCE-50.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio14.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$22.0M$381.0M$87.0M$0
Operating Profit$-83.0M$-201.0M$39.0M$-315.0M$-153.0M
Net Profit$-88.0M$-198.0M$49.0M$-302.0M$-145.0M
EPS$-1.52$-2.98$0.70$-4.43$-1.53
Op Margin—-905.7%10.2%-360.2%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$106.0M$391.0M$517.0M$194.0M$333.0M
Total Liabilities$257.0M$51.0M$84.0M$29.0M$27.0M
Cash$50.0M$63.0M$170.0M$77.0M$227.0M
Borrowings$0$6.0M$4.0M$2.0M$6.0M

Latest News

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight PR Newswire · Jul 7, 2026 Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? Insider Monkey · Jun 30, 2026 Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 Business Wire · Jun 23, 2026 Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape MarketBeat · Jun 10, 2026 Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 Business Wire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-75.0M$-180.0M$12.0M$-168.0M$-123.0M
Investing Cash Flow$-47.0M$-242.0M$91.0M$75.0M$14.0M
Financing Cash Flow$-2.0M$-1.0M$-3.0M$-2.0M$-3.0M
Net Cash Flow$37.0M$13.0M$108.0M$-92.0M$149.0M
Free Cash Flow$-75.0M$-182.0M$11.0M$-168.0M$-123.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-11.27%
Quick Ratio17.85
Interest Coverage—
Return 1Y109.65%
Return 3Y-23.25%
Return 5Y—

Ownership

Insiders Held7.89%
Institutions Held105.37%
Institutions Float Held114.39%
Institutional HolderSharesReport Date
FMR, LLC16,630,5412026-03-31
Blackrock Inc.8,828,8362026-03-31
Perceptive Advisors Llc8,284,8822026-03-31
TCG Crossover Management, LLC6,243,8122026-03-31
Commodore Capital Lp5,650,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
CVACCureVac N.V. $4.66 +0.00% 5.69 $1.05B 0.00%
IMTX $8.24 -4.52% -4.98 $1.10B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About AMLX

AMLX is led by CEO Joshua Cohen, employs 123 people, headquartered in US, publicly traded since 2022.

AMLX stock trades at $22.82 with a market capitalization of $2.54B. The stock is valued at a price-to-earnings (P/E) ratio of -8.69, price-to-book of 3.62, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.80 and $22.82, and currently trades at its 52-week high.

On profitability, AMLX generates a return on equity (ROE) of -47.54%, return on capital employed of -50.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides